[Pharmacodynamic properties of a combination of met-enkephalin and alpha 1-13 adrenocorticotropic hormone].
ENKORTEN is newly registered drug in Bosnia and Herzegovina. It consists of two peptide components: met-enkephalin and alpha 1-13-corticotropine (alpha-ACTH 1-13), previously called alpha-melanocyte-stimulating hormone-like (alpha-MSH-like) Met-enkephalin and alpha-MSH exhibited cytoprotective effects individually and statistically significant additive effect was registered when both peptides were applied in combination on the model of ethanol induced gastric lesions in rats. Combination has immunomodulatory effects. Method of selective immunomodulation with antigens and peptides in immunological mediated diseases and malignant tumors is directed towards long-term remission without so many adverse effects characteristic for immunosuppressive drugs. Adverse reactions registered for so long with ENKORTEN were mild, reversible and usually developed during and immediately after drug application.
Institut za farmakologiju, klinicku farmakologiju i toksikologiju, Medicinski fakultet Univerziteta u Sarajevu.
Nedzad
N
Mulabegović
Maida
M
Rakanović-Todić
D000818:Animals; D004338:Drug Combinations; D004744:Enkephalin, Methionine / Q000493:pharmacokinetics / Q000494:pharmacology*; D006728:Hormones / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D000521:alpha-MSH / Q000493:pharmacokinetics / Q000494:pharmacology*
D004338:Drug Combinations; C530167:Enkorten; D006728:Hormones; D007155:Immunologic Factors; D018377:Neurotransmitter Agents; D000521:alpha-MSH; D004744:Enkephalin, Methionine